RADNOSTIX, INC.

radnostix.com

What Do They Do?

Produces radioisotope products for medical, research and industrial customers, including radiopharmaceuticals, cobalt sources and calibration standards.

How Do They Make Money?

Customers buy products, with sales counted when products ship; some cobalt contracts include preliminary payments well before shipment.

revenue

Segment	Share	How money arrives
Theranostics Products Sold outright	52% FY2022: 54%	Sold outright
Cobalt Products Sold outright	13% FY2022: 10%	Sold outright
Calibration & Reference Products Sold outright	33%	Sold outright
Medical Device Products Sold outright	1.8%	Sold outright
Fluorine Products	0.0% FY2022: 0.0%

Who Are Their Customers?

Radiopharmacies buy the company’s I-131 directly. Other medical products generally reach end users through distributors, while industrial products are sold directly to end users or equipment makers that bundle them.

Do Revenues Turn Into Profits?

Not on paper. It lost $908K in FY2025, but brought in more cash than it spent: $86K of free cash flow.

Operating income, FY2025

−7% of revenue

▼ Now a loss vs FY2024 ($6.9K, 0%)

Net income, FY2025

−7% of revenue

▼ Now a loss vs FY2024 ($8.6K, 0%)

Free cash flow, FY2025

1% of revenue

▲ Now profitable vs FY2024 (−$82.4K, −1%)

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jun 30, 2026

Revenue: ▼ −27%; vs $3.7M in Q2 FY2025
Net income: ▲ +449% (Loss); vs −$160.8K in Q2 FY2025

Theranostics Products share of revenue vs 52.1% in Q2 FY2025

Jul 1, 2026 Bought assets tied to the Lara System and Ellexa Explorer The assets include related accessories, software, regulatory approval, intellectual property, hardware, and licenses.

Growing. Revenue grew 35% in 4 years, from $9.7M in FY2021 to $13.1M in FY2025, about 8% a year.

A medical-device business The older report described radiochemicals, nuclear medicine standards, cobalt and fluorine products; the latest adds medical devices, including lung-imaging products, a capsule system under development and third-party radiosynthesis equipment.

Revenue over time

Theranostics Products Cobalt Products Calibration & Reference Products Medical Device Products Fluorine Products Nuclear Medicine Products Radiochemical Products

$20M$10M$0

FY2021 FY2022 FY2023 FY2024 FY2025

Who Do They Compete With?

Competes with Jubilant DraxImage, Eckert & Ziegler, Epsilon Radioactive Sources, Nordion, NTP, BRIT, CIRC, and Rosatom

Comments